Population-Based Drug-Induced Agranulocytosis
The DOI matches its Crossref record.
Abstract
BACKGROUND: Since the publication of a major international case-control study on the risk of agranulocytosis associated with the use of medicines in the 1980s, many new drugs have been introduced in therapeutics. METHODS: Seventeen units of hematology contribute to the case-control surveillance of agranulocytosis and aplastic anemia in Barcelona, Spain. After a follow-up of 78.73 million person-years, 177 community cases of agranulocytosis were compared with 586 sex-, age, and hospital-matched control subjects with regard to previous use of medicines. RESULTS: The annual incidence of community-acquired agranulocytosis was 3.46:1 million, and it increased with age. The fatality rate was 7.0%, and the mortality rate was 0.24:1 million. The drug most strongly associated with a risk of agranulocytosis was ticlopidine hydrochloride with an odds ratio (OR) of 103.23 (95% confidence interval [CI], 12.73-837.44), followed by calcium dobesilate (OR, 77.84 [95% CI, 4.50-1346.20]), antithyroid drugs (OR, 52.75 [95% CI, 5.82-478.03]), dipyrone (metamizole sodium and metamizole magnesium) (OR, 25.76 [95% CI, 8.39-179.12]), and spironolactone (OR, 19.97 [95% CI, 2.27-175.89]). Other drugs associated with a significant risk were pyrithyldione, cinepazide, aprindine hydrochloride, carbamazepine, sulfonamides, phenytoin and phenytoin sodium, beta-lactam antibiotics, erythromycin stearate and erythromycin ethylsuccinate, and diclofenac sodium. Individual attributable incidences for all these drugs, which collectively accounted for 68.6% of cases, were less than 1:1 million per year. CONCLUSIONS: Agranulocytosis is rare but serious. A few drugs account for two thirds of the cases. Our results also provide reassurance regarding the risk associated with a number of newly marketed drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Adverse effects of antiepileptic drugs
Perucca, P., & Gilliam, F. G. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70153-9 · Cited by 694
Systematic Review: Agranulocytosis Induced by Nonchemotherapy Drugs
Andersohn, F., Konzen, C., & Garbe, E. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-9-200705010-00009 · Cited by 479
“Anticonvulsants Phenytoin (1/2) Carbamazepine (4), lamotrigine (3) Antineoplastics Amygdalin (1/0) Aminoglutethimide (2), flutamide (1), imatinib (3), nilutamide (1), rituximab‡ (25) Antirheumatics Infliximab (1/0), levamisole (2/6) Gold (5), penicillamine (2), sulfasalazine (12) Antithyroid drugs Propylthiouracil (1/…”
Idiosyncratic Adverse Reactions to Antiepileptic Drugs
Zaccara, G., Franciotta, D., & Perucca, E. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2007.01041.x · Cited by 364
Metadata
- Authors
- Ibáñez, L., Vidal, X., Ballarín, E., & Laporte, J.-R.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2005-04-25
- Volume
- 165
- Issue
- 8
- Pages
- 869
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2108713627
- Cited by
- 233
- References
- 0
- FWCI
- 7.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.